Company intelligence / Profile preview
Spine BioPharma, Inc.
New York, New York, United Statesspinebiopharma.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
Spine BioPharma’s lead candidate, SB-01 For Injection—a synthetic peptide TGF-Beta antagonist—has completed enrollment in Phase 3 clinical trials targeting chronic low back pain due to degenerative disc disease. The therapy aims to reduce pain, restore function, and potentially slow or stop disease progression without surgery or opioids. No final Phase 3 results have been published yet as of May 2025.
- Therapeutic areas
- NeurologyRheumatology
- Modalities
- Synthetic peptide therapeutics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Ensol Biosciences (expanding indications for SB‑01)Yuhan Corp. (SB‑01 also referred to as YH14618)Pacira Biosciences – investor and strategic partner supporting development of Remedisc/SB‑01Viscogliosi Bros., Cercano Management – investors
Beyond the preview
Go deeper on Spine BioPharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spine BioPharma, Inc..